Accumetrics completes enrollment phase of GRAVITAS clinical trial Accumetrics, Inc.g., coronary attack, stent thrombosis) pursuing percutaneous coronary intervention .S. And Canada, and has enrolled 2 around,800 patients. We are thrilled to have got concluded the enrollment stage of the GRAVITAS trial, said Jeff Dahlen, Ph.D., Vice President, Clinical and Regulatory Affairs of Accumetrics. Â.Additional eligibility requirements had been receipt of insulin-pump therapy for at least 3 months, a glycated hemoglobin level of 7 to 10 percent, a body-mass index below the 97th %ile for the patient’s age, and an ability to adhere to the trial instructions. The main exclusion requirements had been a concomitant disease, participation in another study, pregnancy, a past background of diabetic ketoacidosis or severe hypoglycemia within the past month, and the use of medications or the current presence of other conditions that might impact metabolic control, compromise safety, or prevent participants from completing the scholarly study.